

Nombre: Emilio Maseda Garrido

Año y Universidad por la que obtuve el Grado de Doctor: Año 2000.  
Universidad Autónoma de Madrid

Especialidad: Anestesiología y Reanimación.

Centro: Hospital Universitario La Paz. Paseo de la Castellana 261. 28046  
Madrid. Unidad de Reanimación Polivalente

Puesto de Trabajo: Coordinador Unidad de Reanimación Polivalente, Hospital  
Universitario La Paz

### Curriculum Vitae:

1. **Maseda E**, Suarez-de-la-Rica A, Anillo V, Tamayo E, García-Bernedo CA, Ramasco F, Villagran MJ, Maggi G, Gimenez MJ, Aguilar L, Granizo JJ, Buño A, Gilsanz F. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study. *J Crit Care*. 2014 Dec 31. pii: S0883-9441(14)00504-8. doi:10.1016/j.jcrc.2014.12.014. [Epub ahead of print] PubMed PMID: 25600574.
2. Vicent JL, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, et al. (**Maseda E**). Assessment o the worldwide burden of critical illness: the intensive care over nations (ICON) audit. *Lancet Respir Med* 2014; 2:380-6
3. Zaragoza R, Ferrer R, **Maseda E**, Llinares P, Rodríguez A; EPICO PROJECT GROUP. EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations. *Rev Esp Quimioter*. 2014 Sep;27(3):196-212
4. **Maseda E**, Aguilar L, Gimenez MJ, Gilsanz F. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. *Expert Rev Anti Infect Ther*.2014 Nov;12(11):1311-24
5. Zaragoza R, Ferrer R, **Maseda E**, Llinares P, Rodriguez A; EPICO Project Group. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations. *Rev Iberoam Micol*. 2014 Jul-Sep;31(3):157-75
6. **Maseda E**, Grau S, Villagran MJ, Hernandez-Gancedo C, Lopez-Tofiño A, Roberts JA, Aguilar L, Luque S, Sevillano D, Gimenez MJ, Gilsanz F. Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. *J Antimicrob Chemother*. 2014 Jun;69(6):1624-32

7. **Maseda E**, Mensa J, Valía JC, Gomez-Herreras JI, Ramasco F, Samsó E, Chiveli MA, Pereira J, González R, Aguilar G, Tamayo G, Ojeda N, Rico J, Giménez MJ, Aguilar L. Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. *Rev Esp Anesthesiol Reanim*. 2014 Mar;61(3):e1-e19
8. van den Boogaard M, Schoonhoven L, **Maseda E**, Plowright C, Jones C, Luetz A., Sackey PV, Jorens PG, Aitken LM, van Haren FM, Donders R, van der Hoeven JG., Pickkers P. Recalibration of the delirium prediction model for ICU patients (PRE-DELIRIC): a multinational observational study. *Intensive Care Med*. 2014 Jan 18.
9. **Maseda E**, Hernandez-Gancedo C, Lopez-Tofiño A, Suarez-de-la Rica A, Garcia-Bujalance S, Gilsanz F. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by *Clostridium difficile* infection in a patient with oral cancer admitted to the Surgical Critical Care Unit. *Rev Esp Quimioter*. 2013 Dec;26(4):375-7.
10. **Maseda E**, Mensa J, Valía JC, Gomez-Herreras JI, Ramasco F, Samsó E, Chiveli MA, Pereira J, González R, Aguilar G, Tamayo G, Ojeda N, Rico J, Gimenez MJ, Aguilar L. Bugs, hosts and ICU environment: Countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. *Rev Esp Quimioter*. 2013 Dec;26(4):312-331
11. Zaragoza R, Llinares P, **Maseda E**, Ferrer R, Rodríguez A; Épico Project Group. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. *Rev Esp Anesthesiol Reanim*. 2013 Aug-Sep;60(7):e1-e18
12. Mensa J, Soriano A, Llinares P, Barberán J, Montejo M, Salavert M, Alvarez-Rocha L, **Maseda E**, Moreno A, Pasquau J, Gómez J, Parra J, Candel J, Azanza JR, García JE, Marco F, Soy D, Grau S, Arias J, Fortún J, de Alarcón CA, Picazo J; Sociedad Española de Quimioterapia (SEQ); Sociedad Española de Medicina Interna (SEMI); GTIPO-Sociedad Española de Anestesiología y Reanimación. [Guidelines for antimicrobial treatment of the infection by *Staphylococcus aureus*]. *Rev Esp Quimioter*. 2013 Jan;26 Suppl 1:1-84
13. Zaragoza R, Llinares P, **Maseda E**, Ferrer R, Rodríguez A; Grupo Proyecto Épico. [Épico project: Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients]. *Rev Iberoam Micol*. 2013 Jul-Sep;30(3 Suppl 1):135-49.

14. Bermejo C, **Maseda E**, Salgado P, Gabilondo G, Gilsanz F. [Septic shock due to a community acquired *Clostridium difficile* infection. A case study and a review of the literature.]. *Rev Esp Anesthesiol Reanim*. 2013 Jun 1. pii: S0034-9356(13)00097-2. doi: 10.1016/j.redar.2013.04.005
15. Zaragoza R, Llinares P, **Maseda E**, Ferrer R, Rodríguez A; Épico Project Group. Épico project. Development of educational recommendations using the DELPHI technique on invasive candidiasis in non-neutropenic critically ill adult patients. *Rev Iberoam Micol*. 2013 Jul-Sep;30(3):135-49.
16. **Maseda E**, Denis SE, Riquelme A, Gilsanz F. Use of tigecycline in critically ill patients with serious nosocomial intra-abdominal infections. *Rev Esp Quimioter*. 2013 Mar;26(1):56-63.
17. **Maseda E**, Maggi G, Gomez-Gil R, Ruiz G, Madero R, Garcia-Perea A, Aguilar L, Gilsanz F, Rodriguez-Baño J. Prevalence of and risk factors for biliary carriage of bacteria showing worrisome and unexpected resistance traits. *J Clin Microbiol*. 2013 Feb;51(2):518-21.
18. Maggi G, **Maseda E**, Rice AG, Rodriguez FG. Pneumocystis jirovecii pneumonia in an immunocompetent patient. *Surg Infect (Larchmt)*. 2012 Jun;13(3):183.
19. **Maseda E**, Gilsanz F. [Candida peritonitis in a haemodynamically stable patient. First choice of antifungal treatment ... fluconazole?]. *Rev Iberoam Micol*. 2012 Apr-Jun;29(2):81-4.
20. **Maseda E**, Gilsanz F. [Duration of antibiotic therapy in intraabdominal infections]. *Enferm Infecc Microbiol Clin*. 2010 Sep;28 Suppl 2:49-52.
21. Candel FJ, Martínez-Sagasti F, Borges M, **Maseda E**, Herrera-Gutiérrez M, Garnacho-Montero J, Maynar FJ, Zaragoza R, Mensa J, Azanza JR. [Endotoxin adsorption as adjuvant therapy in gram negative severe sepsis]. *Rev Esp Quimioter*. 2010 Sep;23(3):115-21.
22. Guirao X, Arias J, Badía JM, García-Rodríguez JA, Mensa J, Alvarez-Lerma F, Borges M, Barberán J, **Maseda E**, Salavert M, Llinares P, Gobernado M, García Rey C. [Guidelines for the empirical antibiotic treatment of intra-abdominal infections]. *Rev Esp Anesthesiol Reanim*. 2010 Jan;57(1):41-60
23. Guirao X, **Maseda E**, Barberán J. [Antibiotics in the treatment of intra-abdominal infection]. *Rev Esp Anesthesiol Reanim*. 2010 Jan;57(1):1.
24. Guirao X, Arias J, Badía JM, García-Rodríguez JA, Mensa J, Alvarez-Lerma F, Borges M, Barberán J, **Maseda E**, Salavert M, Llinares P, Gobernado M, García Rey C. [Recommendations in the empiric anti-

infective agents of intra-abdominal infection]. Cir Esp. 2010  
Feb;87(2):63-81.